



Contents PAGE

President's Message			
AMP Strategic Plan			
Mission Statement			
Vision Statement.			
Core Principles			
2019 Board of Directors and Committee Chairs 6			
Affiliations			
Organizational Relationships			
Advocacy and Clinical Practice			
Membership and Annual Meeting Overview 9			
International Education Initiatives			
Financial Statement			



ROM THE PRESIDENT

Dear Colleagues,

This year, AMP celebrated its 25th anniversary at our annual meeting in Baltimore, Maryland. What an adventure it has been! From assembling at small workshops to gathering in bustling Expo Halls around the globe, AMP has truly grown into an international, diverse, and dynamic community.

AMP brings together molecular pathologists, clinical laboratorians, basic and translational scientists, technologists and trainees. Together, we advance the clinical practice, science, and excellence of our field to provide the highest quality health care for patients. Now more than ever, molecular testing is at the forefront of modern medicine.



AMP Presidents and JMD Editors-in-Chief celebrate AMP's 25th anniversary and JMD's 20th anniversary with custom cakes at the 2019 Annual Meeting & Expo.

AMP develops clinical practice guidelines and shares ground-breaking research in our foremost academic publication, *The Journal of Molecular Diagnostics*. We advocate for patients at our places of work, as well as in the halls of government and regulatory agencies. We collaborate to create a comprehensive catalog of educational offerings, and we exchange key knowledge at our professional meetings.

In 2019, our Board of Directors conducted extensive visioning exercises to chart AMP's future, approving programs that will enhance the value of AMP membership for many years to come. In addition, AMP hosted its second Global Congress on Molecular Pathology in May in Hong Kong.

Serving as your President has been a true honor. I look forward to our community's continued successes.

Sincerely,

Victoria M. Pratt, PhD, FACMG Indiana University School of Medicine


Stateore Pan MISSION VISION PRINCIP

AMP'S STRATEGIC PLAN IS DYNAMIC.

Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles, which were updated this year.

MISSION STATEMENT

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** is a not-for-profit scientific society that advances the **CLINICAL PRACTICE**, **SCIENCE**, and **EXCELLENCE** of molecular and genomic laboratory medicine through **EDUCATION**, **INNOVATION**, and **ADVOCACY** to enable highest quality health care.



This year, AMP's Board of Directors worked hard on evaluating our mission and vision. The field of molecular diagnostics is ever evolving and this important exercise lead to a decision to introduce a new vision for the association.

VISION

The **ASSOCIATION FOR MOLECULAR PATHOLOGY** provides global expertise in molecular testing that drives patient care.

CORE PRINCIPLES

S T A T E M E N T

- Quality Health Care Through **EXCELLENCE** in Clinical Molecular Testing
- Fostering the GLOBAL COMMUNITY of Molecular Pathology Professionals
- COLLABORATION to Advance Molecular Pathology
- ADVOCACY that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- **INNOVATION** to Transform Patient Care









OF

Frederick S. Nolte, PhD Medical University of South Carolina

> Somak Roy, MD University of Pittsburgh Medical Center

Roger D. Klein, MD, JD Roger D Klein, MD, JD

INVITED GUEST INTERNATIONAL AFFAIRS COMMITTEE CHAIR Rami Mahfouz, MD, MPH American University of Beirut Medical Center

EXECUTIVE DIRECTOR Mary Steele Williams, MNA, MT(ASCP)SM, CAE

ASSOCIATION FOR MOLECULAR PATHOLOGY 2019 ANNUAL REPORT

PROFESSIONAL RELATIONS COMMITTEE CHAIR Jordan Laser, MD Northwell Health

COMMITTEE CHAIR

Dan Jones, MD, PhD The Ohio State University **ECONOMIC AFFAIRS**

COMMITTEE CHAIR Samuel K. Caughron, MD MAWD Pathology Group, PA

MEMBERSHIP AFFAIRS COMMITTEE CHAIR

Midhat S. Farooqi, MD, PhD University of Missouri-Kansas City School of Medicine

University of Rochester Medical Center Univeristy of North Carolina **TRAINING & EDUCATION**

COMMITTEE CHAIR Cecilia Ching Sze Yeung, MD Fred Hutchinson Cancer Research Center

GENETICS SUBDIVISION CHAIR Thomas W. Prior, PhD

Case Western University

BOARD

PROGRAM COMMITTEE CHAIR

Bringham & Women's Hospital

PUBLICATION & COMMUNICATION COMMITTEE CHAIR

Neal Lindeman, MD

Paul G. Rothberg, PhD

HEMATOPATHOLOGY SUBDIVISION CHAIR Annette Kim, MD, PhD Brigham and Women's Hospital

AMP

Victoria M. Pratt, PhD

PRESIDENT-ELECT

COMMITTEE CHAIR

Karen Weck, MD

PAST PRESIDENT

School of Medicine

CLINICAL PRACTICE

SECRETARY-TREASURER

Indiana University Medical Center

AND STRATEGIC OPPORTUNITIES

AND NOMINATING COMMITTEE CHAIR

Kojo S. J. Elenitoba-Johnson, MD

University of Pennsylvania, Perelman

University of Washington Medical Center

AND FINANCE COMMITTEE CHAIR Daniel E. Sabath, MD, PhD

PRESIDENT

DIRECTORS INFECTIOUS DISEASES SUBDIVISION CHAIR

INFORMATICS SUBDIVISION CHAIR

SOLID TUMORS SUBDIVISION CHAIR





INTERNATIONAL AFFILIATES

The Hong Kong Society for Molecular Diagnostic Sciences (2013) The Molecular Pathology Association of India (2013) The Korean Society for Laboratory Medicine (2013) The German Society of Pathology (2015) Brazilian Society of Clinical Pathology and Laboratory Medicine (2017) The Italian Society of Pathology and Translational Medicine (2017) American University of Beirut Medical Center (2018) Middle East Molecular Biology Sources (2019)

O R G A N I Z A T I O N A L R E L A T I O N S H I P

- **AMP** maintains **MEMBERSHIP** in the following organizations:
 - The Pathology Roundtable
 - Cancer Leadership Council (CLC)
 - Federation of American Societies for Experimental Biology (FASEB)
 - Global Alliance for Genomic Medicine
 - Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
 - Intersociety Pathology Council (IPC)
 - Personalized Medicine Coalition (PMC)

AMP maintains **RELATIONSHIPS** with many organizations, including but not limited to:

- Representative to ASCO CancerLinQ Steering Committee
- Cooperating Society of the American Board of Pathology (ABP)
- Steering Committee, NIST Genome in A Bottle Consortium
- Associate Member of the Intersociety Council for Pathology Information (ICPI)
- · Sponsor of the National Academies Roundtable on Genomics and Precision Health
- Representatives to FNIH Biomarkers Consortium Steering Committees
- Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
- Representative to the CAP Molecular Oncology Committee



AMP





MOLECULAR MEDICINE

AMP ADVOCATES for excellence in molecular testing in clinical laboratories. We advance the field and practice of molecular pathology by representing the membership to the federal agencies and members of Congress to inform and influence public policy. AMP's clinical and scientific affairs initiatives aim to transform patient care through innovation. **INNOVATION**.

A D V O C A C Y

In 2019, around 60 members participated in AMP's Advocacy Day on Capitol Hill, meeting with policymakers to discuss regulation, reimbursement, and advancing patient care. In addition, AMP led and participated in numerous joint advocacy initiatives, hosted two "lunch and learns" with patient advocates, and submitted **35 ADVOCACY COMMENT LETTERS & POSITION STATEMENTS** on issues such as:

- National Coverage Determination for Next Generation Sequencing for Advanced Cancer Patients
- Draft Bills on Oversight of Laboratory Developed Testing Procedures
- Local Coverage Determinations for Molecular Pathology Procedures
- Protecting Access to Medicare Act (PAMA) Data Reporting and Implementation
- Updated AMP Position Statement on Consumer Genomic Testing
- Best Practices for Clinical Pharmacogenomic Testing
- Potential concerning updates to Section 101 of the Patent Act

INNOVATION & IMPROVED PATIENT CARE

In 2019, over **165 MEMBER VOLUNTEERS** worked on behalf of AMP to foster excellence in clinical practice and patient care, serving on AMP-led working groups or as AMP representatives to external collaborative projects and committees. The vast majority of AMP-led CPC Working Groups have representation from other organizations, to include the most recent AMP report:

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists

J Mol Diagn. 2019 September; 21(5):746-755









Recipients of the Jeffrey A. Kant Leadership Award gathered at the 2019 Annual Meeting & Expo.



²⁰¹⁹ AMP Global Organizing Committee in Hong Kong.

AMP ended the year with continued membership growth for the 13th straight year, rising from **2,514** in 2018 to **2,522** in 2019. Indicators suggest that growth will continue for the coming years. AMP members can be found in **57 COUNTRIES**.

Attendance continued to be strong at the **2019 ANNUAL MEETING**. We welcomed **2,150** attendees and over **170** companies. In addition, we welcomed nearly **500** attendees and **30** exhibiting companies at **AMP GLOBAL**, our first meeting in Asia.

		SCIENTIFIC
YEAR	LOCATION	ATTENDEES
2011	GAYLORD TEXAN, TX	1,343
2012	LONG BEACH, CA	1,674
2013	PHOENIX, AZ	1,720
2014	WASHINGTON, DC	1,944
2015	AUSTIN, TX	2,084
2016	CHARLOTTE, NC	2,022
2017	SALT LAKE CITY, UT	2,201
2018	SAN ANTONIO, TX	2,106
2019	BALTIMORE, MD	2,150

AMP MEMBERS BY DEGREE:

PhD 900 (35.7%)	
MD 1104 (43.8%)	
Other 518 (20.5%)	

COLENITIELC















AMP's educational initiatives continue to reach a global audience. In 2019, AMP hosted its second **GLOBAL CONGRESS ON MOLECULAR PATHOLOGY** meeting in **HONG KONG**. AMP invited speakers also presented at three AMP-affiliate society conferences in **INDIA**, **KOREA** .and **BRAZIL**. In addition, the International Affairs Committee hosted a luncheon for international attendees at the AMP 2019 Annual Meeting, entitled "Certification in Molecular Pathology outside the USA".

Two new grant-supported AMP Education webinar series were launched in 2019: An additional two-part series on Tumor Mutational Burden and a three-part series on PARP Inhibitors. Each series was recorded and is available on AMP's Online Learning Platform, AMPED_{TM}, through 2021. Other supported content (Advancing Patient Care in NSCLC: Breaking Down Barriers and the 2018 TMB webinar series) is also available. All registration and continuing education credit for these grant-supported online offerings are available at no charge.

The AMP learning management system, AMPED_{TM}, has more than **200** hours of cutting-edge molecular pathology content delivered by experts in the field. To learn more, visit educate.amp.org






AMP's fiscal footing is solid, allowing it to dedicate significant resources to each of its strategic initiatives.

S

STRATEGIC INITIATIVE REVENUE OVER EXPENSES	2019	2018	2017
Advocacy	\$ (612,500)	\$ (490,772)	\$ (437,181)
Communications & Outreach	\$ (149,155)	\$ (125,071)	\$ (193,658)
Education	\$ 1,832,607	\$ 2,021,273	\$ 1,932,749
Innovation & Improved Patient Care	\$ (290,091)	\$ (250,296)	\$ (288,701)
Membership & Management Services	\$ (76,388)	\$ (220,128)	\$ (208,213)
EXCESS REVENUE OVER EXPENSES	\$ 704,474	\$ 935,006	\$ 804,996



Sojet

602

TAFS

CCGGTQUEL

TTCCCC



FREE



Association for Molecular Pathology

6120 Executive Boulevard Suite 700 Rockville, Maryland, 20852







www.amp.org

